Navigation Links
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
Date:9/18/2013

n addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products.  Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products.  In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates.  Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products.  Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates.  Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

Additional Information
This communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Onyx Pharmaceuticals, Inc. or any other securities.  Arena Acquisition Company and Amgen Inc. have filed a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the United States Securities and Exchange Commission (the "SEC") and a Solicitation/Recommendation Statement on Schedule 14D-9 has bee
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
2. Amgen To Participate At Citis 8th Annual Biotech Conference
3. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
4. Amgen to Highlight New Data at Upcoming ESC Congress 2013
5. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
6. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
9. Amgen Announces Webcast of 2013 Second Quarter Financial Results
10. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 18 New data evaluating the impact of screening ... prostate cancer screening. The Prostate Conditions Education Council ... a leader in prostate cancer screening, announced today that ... from two studies, including the preliminary data from the ...
... Platform Designed for Radial Strength, FlexibilityHOUSTON, March 18 ... in the development and marketing of minimally invasive ... Drug Administration (FDA) has approved an investigational device ... its SUPERA stent, a novel stent platform designed ...
Cached Medicine Technology:Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 2Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 3U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Date and ... at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa 19009 , ... host a day-long seminar featuring New York Times best-selling author Sam Keen based on ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... today the launch of its enhanced, cloud-based mobile ePrescribing application. The release of ... on improving prescriber usability. A leader in health technology, RxNT was one of ...
(Date:9/2/2015)... Waltham, MA (PRWEB) , ... September 02, 2015 ... ... often get swamped with a large stream of mixed documents that include EOBs, ... the various documents, while extracting the data needed to reconcile their billing, with ...
(Date:9/2/2015)... ... September 02, 2015 , ... Good health and a ... Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf ... the foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer ...
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda ... in commemorating “Hunger Action Month” during the entire month of September. In ... will be dedicating its efforts this September to an awareness campaign educating legislators ...
Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4
... ... Fax Technology and New HTTPS Platform, , ... Tigard, OR and Salem, OR (PRWEB) September 23, 2009 -- ... FaxBack, a leading provider of reliable VoIP Fax solutions for SMB, enterprise and carrier ...
... Oakstone ... the American College of Physicians. Available in two versatile audio formats designed to allow physicians ... ... the first section of the MKSAP 15 Audio Companion . Available in compact disc ...
... ... medical device testing , ... OH (PRWEB) September 23, 2009 -- NAMSA,s Analytical Chemistry department is on the move. ... facility is now in use at NAMSA. , , , , ,The ...
... with negative sputum tests by a new method, according ... cause of death worldwide, and while the diagnosis of ... can be identified on sputum microscopy, in about half ... making another diagnostic option critical in efforts to control ...
... NEW YORK, Sept. 22 Preet Bharara, the U.S. Attorney for ... formerly the senior manager of human resources of Hitachi America Ltd. ... months in prison for defrauding the Hitachi America Group Health and ... was imposed by U.S. District Judge Colleen McMahon. Dowd pleaded guilty ...
... , The LFA asks people to join them and ... an FDA-approved medication specifically for lupus , , ... Drug Administration (FDA) approved a medication to treat lupus -- when Dwight ... and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched ...
Cached Medicine News:Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 2Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 3Health News:Oakstone Produces Self-Assessment Audio Updates to Support the American College of Physicians' MKSAP 15 2Health News:NAMSA Unveils New, Larger State-of-the-Art Analytical Chemistry Facility 2Health News:New test quickly ID's active TB in smear-negative patients 2Health News:Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: